Tim Urquhart is a Research Analyst at Janus Henderson Investors, a position he has held since joining the firm in 2002.
Tim Urquhart
A new round of drug pricing reform
The U.S. Department of Health and Human Services wants to eliminate drug manufacturer rebates in Medicare, a move that could improve affordability for consumers. Portfolio Manager Ethan Lovell and Research Analyst Rich Carney, of the Global Life Sciences team, explain why the change is significant and how it could potentially benefit the health care sector in the long run.
John Teng
John Teng is an Investment Analyst on the Asia ex Japan Equity Team at Janus Henderson Investors.
Mike Talaga, CFA
Mike Talaga is Head of Credit Research at Janus Henderson Investors, a position he has held since 2023. Mike joined the firm in 2015 as a credit analyst and became head of credit research, North America in 2022.
Aaron Scully, CFA
Aaron Scully is a Portfolio Manager on the Global Sustainable Equity Team at Janus Henderson Investors, a position he has held since 2019.
Aaron Schaechterle
Aaron Schaechterle is a Research Analyst at Janus Henderson Investors primarily focused on small- and mid-capitalisation companies in the Health Care and Industrials & Materials sectors.
Steven Quinn
Steve Quinn is Head of ETP Distribution at Janus Henderson Investors.
Tom Roller, CFA
Tom Roller is a Research Analyst at Janus Henderson Investors primarily focused on small- and mid-cap stocks in the Consumer and Communications sectors.
Alex Roitz, CFA
Alex Roitz is a Client Portfolio Manager at Janus Henderson Investors responsible for fixed income. Before assuming this role in 2021, he was a director, product specialist at the firm from 2016.
Leah Reed
Leah Reed is a Quantitative Strategist at Janus Henderson Investors.